Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

ESTRADIOL HEMIHYDRATE

All products: general benefit

Other products in the same Health Canada class (G03CA) — coverage varies; not interchangeable

  • Conjugated estrogens (Premarin): general benefit, Limited Use 398
  • Estradiol (Estrace): general benefit, Not a benefit
  • B + estradiol (Vagifem 10): general benefit

Imvexxy · DIN 02503689 · 4mcg · Vag Insert

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Imvexxy · DIN 02503689 Manufacturer: Knight Therapeutics Inc.; listing date 2023-11-30 Health Canada: Marketed since 2023-11-14 · brand IMVEXXY · ATC G03CA03 ESTRADIOL · form Insert · route Vaginal · ingredients ESTRADIOL (ESTRADIOL HEMIHYDRATE) 4 MCG/INSERT · company Knight therapeutics inc. · schedule Prescription
Check this DIN again · Health Canada product record

Imvexxy: Formulary list price $3.6942/unit (unit not stated in source; not the patient's cost)

Ministry pays: $3.6942 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99313 · Verify on the e-Formulary ↗ (DIN 02503689)

Source record
DIN 02503689: Imvexxy Raw flags: sec3=Y Item: 681600079; group id 735; item number 1802; lccId None; manufacturer id KNT Source form: Vag Insert; strength: 4mcg Recorded listing: General benefit Source prices (unrounded): $3.6942; ministry $3.6942 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02503689 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99313
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02503689
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (68:16 Estrogens) and how they are covered

Matched class: 68:16 Estrogens

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ESTRADIOL 17-B, ESTRADIOL HEMIHYDRATE & PROGESTERONE Some products covered without a code (check the product listing): CONJUGATED ESTROGENS, ESTRADIOL 68:16 Estrogens

CONJUGATED ESTROGENS

· 2 products · Limited Use, codes 398 (1), General benefit (1) · strengths: 0.625mg, 0.625mg/g · SR Tab, Vag Cr

ESTRADIOL

· 7 products · Listed, not a benefit (3), General benefit (4) · strengths: 0.5mg, 1mg, 2mg · Tab, Vag Ring

ESTRADIOL 17-B

· 1 products · General benefit · strengths: 10mcg · Vag Tab with Applicator

ESTRADIOL HEMIHYDRATE & PROGESTERONE

· 1 products · General benefit · strengths: 1mg & 100mg · Cap Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 68:16
Full class listing Related classes: 68:04 Corticosteroids, 68:08 Androgens, 68:12 Contraceptives, 68:20 Anti-Diabetic Agents, 68:24 Parathyroid Agents, 68:28 Pituitary Agents, 68:32 Progestogens and Oral Contraceptives, 68:36 Thyroids, 68:38 Anti-Thyroids Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS IMVEXXY ® (17 β-estradiol) is indicated for: • the treatment of postmenopausal moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy. IMVEXXY clinical effectiveness is supported by safety and efficacy data based on a 12-week study. The safety and efficacy of longer-term use of IMVEXXY have not been established (see 14 CLINICAL TRIALS). 1.1 Pediatrics Pediatrics (<18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 1.2 Geriatrics Geriatrics (>65 years of age): There have not been sufficient numbers of geriatric women involved in clinical studies utilizing IMVEXXY to determine whether those over 65 years of age differ from younger subjects in their response to IMVEXXY. https://pdf.hres.ca/dpd_pm/00077738.PDF PM date: AUG 13, 2020 Source product: IMVEXXY; DIN 02503689; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.